Pipeline tracker

Hepatocyte epigenetic reprogramming medicine

PreclinicalEvidence reviewed by an editor

Hepatocyte epigenetic reprogramming medicineNewLimit · Age-related liver dysfunction

Preclinical · Epigenetic reprogramming therapyAs of Sep 25, 2026

On June 2, 2026 NewLimit said it plans a first human trial of its liver reprogramming medicine in 2027 (company blog).

What this stage means

Preclinical means the work so far is in cells, tissues or animals. Most candidates at this stage never become medicines.

A development stage describes where the evidence stands for one specific use. It does not mean the product works for everyone, is available everywhere, or will succeed commercially.

Development stages, sourced

Elsewhere in the pipeline

Selected therapies and technologies at every stage, from preclinical research to approval. Each stage is dated and linked to a primary source.

Full tracker

Casgevy (exagamglogene autotemcel)Vertex Pharmaceuticals and CRISPR Therapeutics · Sickle cell disease and transfusion-dependent beta thalassemia

Approved/cleared · CRISPR/Cas9-edited autologous stem-cell therapyAs of Sep 25, 2026

Intismeran autogene (V940 / mRNA-4157)Moderna and Merck · High-risk resected melanoma (with pembrolizumab)

Phase 3 · Individualized neoantigen mRNA cancer vaccineAs of Sep 25, 2026

CTX112 (zugocabtagene geleucel)CRISPR Therapeutics · Autoimmune diseases incl. systemic lupus erythematosus and systemic sclerosis

Phase 1 · Allogeneic CRISPR-edited CD19 CAR-T cell therapyAs of Sep 25, 2026

da Vinci 5 surgical system — cardiac indicationsIntuitive Surgical · Cardiac procedures incl. mitral valve repair

Approved/cleared · Robotic-assisted surgical systemAs of Sep 25, 2026

Galleri multi-cancer early detection testGRAIL · Multi-cancer screening in adults 50+

Under review · Cell-free DNA methylation blood test (NGS + machine learning)As of Sep 25, 2026

Optive AI software for Swoop portable MRIHyperfine · Point-of-care brain imaging

Approved/cleared · AI image-reconstruction software for portable ultra-low-field MRIAs of Sep 25, 2026

Stages summarise the most advanced publicly documented status for the named use. “Approved” applies to specific indications and regions only. Nothing here is medical or investment advice.